VENT 02
Alternative Names: VENT-02Latest Information Update: 09 May 2024
At a glance
- Originator Ventus Therapeutics
- Class Anti-inflammatories; Neuroprotectants; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurodegenerative disorders
Most Recent Events
- 03 May 2024 Ventus Therapeutics completes a phase I trial in Neurodegenerative disorders (PO)
- 17 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse events data from the phase I trial in Neurodegenerative disorders released by Ventus Therapeutics
- 17 Apr 2024 Ventus Therapeutics plans a phase Ib trial for Parkinson’s disease in the second half of 2024